EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tumor-agnostic drug development in dMMR/MSI-H solid tumors

Deepak Bhamidipati, Vivek Subbiah

Trends in Cancer · 2023-10 · 9 (10) · 828-839

DOI: 10.1016/j.trecan.2023.07.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-10. Verfasst von Deepak Bhamidipati und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) represents a distinct phenotype among solid tumors characterized by frequent frameshift mutations resulting in the generation of neoantigens that are highly immunogenic. Seminal studies identified that dMMR/MSI-H tumors are exquisitely sensitive to immune checkpoint inhibitors, which has dramatically improved outcomes for patients harboring dMMR/MSI-H tumors. Nevertheless, many patients develop resistance to single-agent immune checkpoint blockade, prompting the need for improved therapeutic options for this patient population. In this review, we highlight key studies examining the efficacy of PD1 inhibitors in the metastatic and neoadjuvant setting for patients with dMMR/MSI-H tumors, describe resistance mechanisms to immune checkpoint blockade, and discuss novel treatment approaches that are currently under investigation for dMMR/MSI-H tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsBrain NeoplasmsMicrosatellite InstabilityHumansNeoplastic Syndromes, HereditaryNeoadjuvant Therapy

Stichwörter der Autor:innen

deficient mismatch repairmicrosatellite instability

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address: vivek.subbiah@scri.com.

Förderung

  • NCI

Zitieren

APA

Bhamidipati, D., & Subbiah, V. (2023). Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends in Cancer, 9(10), 828-839. https://doi.org/10.1016/j.trecan.2023.07.002

Vancouver

Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends in Cancer. 2023;9(10):828-839. doi:10.1016/j.trecan.2023.07.002

BibTeX
@article{Bhamidipati2023,
  author = {Bhamidipati, Deepak and Subbiah, Vivek},
  title = {Tumor-agnostic drug development in dMMR/MSI-H solid tumors},
  journal = {Trends in Cancer},
  year = {2023},
  volume = {9},
  number = {10},
  pages = {828--839},
  doi = {10.1016/j.trecan.2023.07.002}
}
Kostenlos starten →